Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-871-2098
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$177.98 million
Profitability
Miscellaneous
Employees114
OptionableOptionable
Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions
What is Akebia Therapeutics' stock symbol?
Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
How were Akebia Therapeutics' earnings last quarter?
Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.18. The biopharmaceutical company earned $53.17 million during the quarter, compared to analysts' expectations of $39.71 million. Akebia Therapeutics had a negative net margin of 30.29% and a negative return on equity of 45.61%. View Akebia Therapeutics' Earnings History.
When is Akebia Therapeutics' next earnings date?
What price target have analysts set for AKBA?
5 brokers have issued 12 month target prices for Akebia Therapeutics' shares. Their predictions range from $9.00 to $22.00. On average, they expect Akebia Therapeutics' stock price to reach $16.1667 in the next twelve months. This suggests a possible upside of 179.7% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.
What is the consensus analysts' recommendation for Akebia Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.
What are Wall Street analysts saying about Akebia Therapeutics stock?
Here are some recent quotes from research analysts about Akebia Therapeutics stock:
- 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (1/16/2019)
- 2. Mizuho analysts commented, "We expect Akebia to compete with two other products within next-generation (HIF-PHI) anemia drugs and we believe order of market entry will be; 1) Fibrogen (FGEN, Buy, $74 PT)’s roxadustat, 2) Akebia’s vadadustat, and 3) GlaxoSmithKline (GSK, Not-rated)’s daprodustat, which we think is ~ 6 months behind vadadustat." (12/4/2018)
- 3. HC Wainwright analysts commented, "Our $42 price target is based on a 13-year DCF analysis of the Hemophilia B (65% (5% POS). We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $820M during 2028. We assume a launch price of $772.5K (durability >5 years), and at peak, we estimate about 775 patients in the U.S. and approximately 1,050 patients in the developed markets who would have received uniQure’s gene therapy, which represents an 50% of the overall commercial opportunity." (6/29/2018)
Has Akebia Therapeutics been receiving favorable news coverage?
Press coverage about AKBA stock has been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akebia Therapeutics earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the near term.
Are investors shorting Akebia Therapeutics?
Akebia Therapeutics saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 5,625,043 shares, a decrease of 61.0% from the December 14th total of 14,427,584 shares. Based on an average daily volume of 1,440,325 shares, the short-interest ratio is presently 3.9 days. Approximately 5.5% of the shares of the stock are short sold. View Akebia Therapeutics' Current Options Chain.
Who are some of Akebia Therapeutics' key competitors?
Some companies that are related to Akebia Therapeutics include Prestige Consumer Healthcare (PBH), Aimmune Therapeutics (AIMT), Arrowhead Pharmaceuticals (ARWR), Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Clovis Oncology (CLVS), Wave Life Sciences (WVE), Myovant Sciences (MYOV), TherapeuticsMD (TXMD), Kiniksa Pharmaceuticals (KNSA), Uniqure (QURE), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR), Rhythm Pharmaceuticals (RYTM) and Amphastar Pharmaceuticals (AMPH).
Who are Akebia Therapeutics' key executives?
Akebia Therapeutics' management team includes the folowing people:
- Mr. John P. Butler, CEO, Pres & Director (Age 55)
- Mr. Michel Dahan, Sr. VP & Chief Bus. Officer (Age 40)
- Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)
- Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)
- Ms. Nicole R. Hadas, Sr. VP, Gen. Counsel & Sec. (Age 46)
Who are Akebia Therapeutics' major shareholders?
Akebia Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.08%), Virtu Financial LLC (0.05%), Lincoln Capital Corp (0.04%) and Bristol Advisors LLC (0.03%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.
Which institutional investors are buying Akebia Therapeutics stock?
How do I buy shares of Akebia Therapeutics?
Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akebia Therapeutics' stock price today?
One share of AKBA stock can currently be purchased for approximately $5.78.
How big of a company is Akebia Therapeutics?
Akebia Therapeutics has a market capitalization of $329.80 million and generates $177.98 million in revenue each year. The biopharmaceutical company earns $-76,910,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Akebia Therapeutics employs 114 workers across the globe.
What is Akebia Therapeutics' official website?
How can I contact Akebia Therapeutics?
Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]
MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
